Hydroxypropyl-beta-cyclodextrin

Phase 3Small molecule

Hydroxypropyl-beta-cyclodextrin is one of 6 small molecule programs targeting Niemann-Pick disease type C. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Niemann-Pick Disease Type CActive, not recruiting

Niemann-Pick Disease Type CPhase 3

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Niemann-Pick Disease Type C

#DrugCompanyPhaseTrials

Acetadote

AArbor Pharmaceuticals, Inc.

Approved

—2

Lithobid

SSolvay Pharmaceuticals

Miplyffa

1 4

N-Acetyl-L-Leucine

IIntraBio Inc

Phase 3

1 5

Hydroxypropyl-beta-cyclodextrin

CCyclo Therapeutics, Inc.

Phase 3

1 6

Hydroxypropyl-β-Cyclodextrin

CCyclo Therapeutics, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Early Alzheimer's Disease1 trial

A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease

Unknown status·CCyclo Therapeutics, Inc.·Phase 2·NCT05607615·90 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Intravenous Trappsol Cyclo (HPBCD) in Niemann-Pick Type C Patients

Completed·CCyclo Therapeutics, Inc.·Phase 1/2·NCT02912793·12 enrolled

Biomarkers1 trial

Study of the Pharmacokinetics of Trappsol and Effects on Potential Biomarkers of Niemann-Pick C1 (NPC1)

Completed·CCyclo Therapeutics, Inc.·Phase 1·NCT02939547·13 enrolled

Niemann-Pick disease type C1 trial

Phase 3 Study to Evaluate Intravenous Trappsol(R) Cyclo(TM) in Pediatric and Adult Patients With Niemann-Pick Disease Type C1

Active, not recruiting·CCyclo Therapeutics, Inc.·Phase 3·NCT04860960·94 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Hydroxypropyl-beta-cyclodextrin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hydroxypropyl-beta-cyclodextrin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hydroxypropyl-beta-cyclodextrin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cyclo Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCyclo Therapeutics, Inc.

Hydroxypropyl-beta-cyclodextrin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Early Alzheimer's Disease1 trial

Safety and Efficacy1 trial

Biomarkers1 trial

Niemann-Pick disease type C1 trial

References

Drug Info

Quick Facts

Related News